Skip to content

Risk Factors of Radiation Pneumonitis

To Investigate Risk Factors of Radiation Pneumonitis, Fibrosis, and Impairment of Quality of Life by Radiotherapeutic Dosimetric and Biological Parameters for Lung Cancer Patients Receiving Thoracic Radiotherapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00155909
Enrollment
53
Registered
2005-09-12
Start date
2003-07-31
Completion date
2006-06-30
Last updated
2005-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiation Pneumonitis

Keywords

Radiation Pneumonitis, Radiotherapy Planning, Computer-Assisted

Brief summary

A prospective observational study to evaluate clinical, dosimetrical, functional, and biological factors in predicting radiation pneumonitis.

Detailed description

We propose a prospective observational study to investigate the combinational effect of radiotherapeutic dosimetric parameters \[mean lung dose & percentage of lung volume receiving at least 20Gy (V20)\] and biological parameters \[interleukin-6(IL6) & transforming growth factor beta (TGFB)\] in predicting radiation pneumonitis, fibrosis, and change of QoL among at least fifty-three lung cancer patients. Eligibility included pathological or cytological proven small cell or non small cell lung cancer, thoracic RT planned for more than 30Gy \[if fraction size \>= 3Gy/fx\] or 40Gy \[if fraction size \< 3 Gy/Fx\], ECOG performance status \[PS\] 0-2, body weight loss \[BWL\] \<=10% in previous 6 months, no prior thoracic RT and signed informed consent prior to study entry. Basic pre-radiotherapy information will be collected, which included BWL, ECOG PS, AJCC stage \[I-IV\], primary lesion site, history of smoking/coexisting lung disease/dosage of chemotherapy/surgical resection, albumin level, and pulmonary function test of FEV1/VC/DLCO(optional). Computed tomography \[CT\] of the whole lung in treatment position with reference mark will be done for calculation of V20 and mean lung dose. Blood test of IL6, TGFB by ELISA will be done before and after RT after storage at -80℃. Bronchial-alveolar lavage test of IL6, TGFB by ELISA will be done before and after RT if clinical available. Self-reported questionnaire \[EORTC C30 & L13\] will be collected before and after RT and in every follow up visits after double-checked by trained assistants. RT must be given by photon energies \>=6MV. Radiation pneumonitis and fibrosis will be assessed according to common toxicity criteria 3 \[CTC-3\] weekly during RT and in every follow up visits. Chi-square test, logistic regression, and proportional hazard ratio method will be used to investigate whether the parameter(s) can be effective in predicting radiation related sequelae.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Non-pregnant adults (age \>=20 y/o) * Pathological or cytological proven small cell or non small cell lung cancer * Thoracic RT planned for more than 30Gy \[if fraction size \>= 3Gy/fx\] or 40Gy \[if fraction size \< 3 Gy/Fx\] * ECOG PS 0-2 * Body weight loss \<=10% in previous 6 months

Exclusion criteria

* prior thoracic RT

Countries

Taiwan

Contacts

Primary ContactChun-Ru Chien, M.D.
stwo@ha.mc.ntu.edu.tw886-2-23123456
Backup ContactWei-Chu Chie, M.D.and PhD
weichu@episerv.cph.ntu.edu.tw886-2-23516478

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026